Objective: The intravenous formulation of lacosamide (LCM) and its good overall tolerability and safety favor the use in status epilepticus (SE). The aim of this systematic review was to identify and evaluate studies reporting on the use of LCM in SE. Methods: We performed a systematic literature search of electronic databases using a combined search strategy from 2008 until October 2016. Using a standardized assessment form, information on the study design, methodologic framework, data sources, efficacy, and adverse events attributed to LCM were extracted from each publication and systematically reported. Results: In total, 522 SE episodes (51.7% female) in 486 adults and 36 children and adolescents were evaluated with an overall LCM efficacy of 57%. Efficacy was comparable between use in nonconvulsive (57%; 82/145) and generalized-convulsive (61%; 30/49; p = 0.68) SE, whereas overall success rate was better in focal motor SE (92%; 34/39, p = 0.013; p < 0.001). The efficacy with later positioning of LCM decreased from 100% to 20%. The main adverse events during treatment of SE are dizziness, abnormal vision, diplopia, and ataxia. Overall, lacosamide is well tolerated and has no clinically relevant drug-drug interactions. Significance: The available data regarding the use of LCM in SE are promising, with a success rate of 57%. The strength of LCM is the lack of interaction potential and the option for intravenous use in emergency situations requiring rapid uptitration.
• Systematic review of use of lacosamide in children and adults with status epilepticus (SE) • In total, 522 SE episodes were identified with an overall lacosamide efficacy of 57% • Efficacy was comparable in nonconvulsive (57%) and generalized-convulsive (61%), and better in focal motor SE (92%) • Main adverse events were dizziness, abnormal vision, diplopia, and ataxia
Status epilepticus (SE) is a life-threatening condition and a medical emergency that imposes a considerable burden on the affected person and society in general.
1,2 A refractory and super-refractory course of SE is associated with increased morbidity and mortality. 3 In such cases, treatment remains difficult, as first-and second-line therapies fail in refractory SE and even general anesthesia fails in superrefractory SE. 4 Due to the severity of illness, limited therapeutic options, and unfavorable outcome, there is a critical need for new therapies to stop ongoing seizure activity. 5 The introduction of new antiepileptic drugs (AEDs) provides an opportunity to achieve better seizure control or an improved safety and tolerability drug profile for some of these patients. AEDs started in SE might be continued for decades in some patients and should therefore provide longterm efficacy and safety. 6 Lacosamide (LCM) was approved in 2008 in the European Union and in the United States as adjunctive therapy for the treatment of focal-onset seizures with or without secondary generalization in adults and adolescents with epilepsy. In 2014, the U.S. Food and Drug Administration (FDA) approved LCM as monotherapy in focal epilepsy. 7, 8 LCM is a functionalized amino acid enhancing the slow inactivation of voltage-gated sodium channels as its mode of action. 9, 10 The slow inactivation results in the stabilization of hyperexcitable neuronal membranes, the inhibition of neuronal firing, and the reduction of long-term channel availability without affecting physiologic function. 9 LCM exhibits several favorable pharmacokinetic characteristics such as rapid absorption, high oral bioavailability (100%) not affected by food, and linear and dose-proportional pharmacokinetics with low interindividual and intraindividual variability. 11, 12 Clinical efficacy was shown in five doubleblind randomized controlled trials, 8, [13] [14] [15] [16] and further safety and tolerability data were generated in extension [17] [18] [19] and postmarketing studies. 20, 21 Due to its intravenous formulation that is bioequivalent with oral preparations and overall good tolerability of LCM, [22] [23] [24] this anticonvulsant was used as a second-line or third-line therapy in SE. H€ ofler and Trinka described in detail the first evidence on the use of LCM in SE between 2009 and 2012. 25 Since then further case series and retrospective analysis were published. The aim of this review is to summarize the current evidence of LCM in SE.
Methods
To identify studies that evaluated the use of LCM in SE, we performed a systematic literature search in electronic databases using a combined search strategy including the following keywords: lacosamide, epilepsy, seizure, and status epilepticus. The search was performed using the PubMed gateway of the MEDLINE database, Cochrane Central Register of Controlled Trials, and the Excerpta Medica dataBASE from 2008 until October 2016. We examined the reference lists of all identified studies for additional studies. Furthermore, review articles on LCM were available. 25, 26 Using a standardized assessment form, information on the study design, methodologic framework, data sources, efficacy, and adverse events attributed to LCM were extracted from each publication and systematically reported. All publications were cross-checked to detect double-reporting of cases. Chi-square tests were performed to assess the efficacy of LCM in SE between nonconvulsive, generalized convulsive and focal motor SE.
Use of LCM in Adults with
Status Epilepticus H€ ofler and Trinka reviewed the literature on LCM in SE published until May 2012. 25 They extracted data on 126 SE episodes from nine retrospective case series; details are in Table 1 . Those case series were further divided into two groups, one group comprising studies with 13 patients or less [27] [28] [29] [30] [31] [32] [33] and the second group containing two studies with 31 and 39 patients each. 34, 35 Among the case series with 13 patients or less, success rates in terminating SE ranged from 0% 29 to 100%, with the three series in which full response was seen comprising 3, 4, and 7 patients, respectively. 27, 30, 31 Two case series included minors: in those, a total of four patients were younger than 18 years (range 12-17 years); see below for further detail. 36, 37 Combining the two studies with 31 patients and more, 39% (27/70) of patients had nonconvulsive SE (NCSE), 37% (26/70) had focal SE, and 24% (17/70) had convulsive SE (CSE). The median dose of LCM was 400 mg in the Osnabr€ uck cohort 35 and 200 mg in the Innsbruck/Salzburg cohort 34 (range in both studies 200-400 mg). In both studies, LCM was given on average as the third AED. In the two larger case series, success rates were 44% 35 and 81%, 34 respectively. Both studies demonstrated that a higher latency from SE onset to LCM therapy was associated with decreased success in terminating SE, with success rates diminishing from 60% and 100% (early administration) to 20% and 75% (refractory SE), respectively. 34, 35 A total of 10 single case reports were included in the review, 25 representing 10 episodes of SE, with 7 NCSE, one CSE, and 2 focal SE. [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] The median initial dose was 100 mg in the nine reports containing this information (range 50-400 mg). LCM was given on average as the fourth drug in the eight reports providing this information (range 2nd-8th AED). One report concerned treatment of a child of 8 years. The success rate of LCM treatment was 100% in the case reports, possibly owing to publication bias; for details, refer to Table 2 . The overall success rate of LCM in SE episodes reviewed by H€ ofler and Trinka was 56% (70/136). 25 There was no overlap between patients included in the case reports and case series.
Since the pivotal review by H€ ofler and Trinka, several additional case series and case reports on SE treatment with LCM have been published; for further detail, refer to Table 1 .
Belcastro et al. 46 reported data from 16 patients in a proof-of-concept, observational study. These patients had partial or complete anterior circulation stroke and developed NCSE in consequence. NCSE was diagnosed clinically and by video-electroencephalography (EEG) according to the Kaplan criteria. 47 LCM was given as the first AED because included patients had contraindications for the use of other drugs such as benzodiazepines or phenytoin. Here, 400 mg i.v. of LCM was applied with a subsequent maintenance dose of 400 mg/day. Treatment was considered successful when patients experienced no NCSE for 24 h following LCM application. Treatment success was evaluated both with EEG recordings and by clinical observation. LCM was deemed effective in 8 (50%) of 16 cases. In 7 (44%) of 16 cases, ictal EEG activity completely disappeared and significantly improved within <60 min in one case. The mean time from stroke or NCSE onset to treatment as well as from treatment onset to NCSE cessation was not reported. 46 Mir o et al. 48 described the efficacy of add-on LCM in 34 patients with refractory SE from a prospective multicenter study. SE was diagnosed according to International League Against Epilepsy (ILAE) criteria and described as refractory when first-and second-line AED therapy had failed. SE cessation was defined as the end of EEG status activity or disappearance of clinical status signs with NCSE ruled out by video-EEG. Treatment success was defined as termination of seizures for at least 48 h after starting LCM with no need for further AEDs. The first LCM bolus dose was on average 323.5 mg (range 100-400 mg). In 22 patients (65%), LCM terminated the SE, and in 17 patients (50%), SE ceased within 12 h after the first administration of LCM. In nine patients, SE was terminated within <60 min after the LCM loading dose. Of note, an order effect was seen regarding LCM efficacy, with LCM being more efficacious (72%) when given as the third/fourth drug than when given as the fifth or later drug (56%). Latency from SE onset to LCM treatment was 60 h on average (range 6-168 h) when LCM was given as third/fourth and 48 h (range 1-250 h) when given as fifth or later drug; in this case, confounding by the time delay from treatment onset seems less likely. 48 Santamarina et al. 49 retrospectively analyzed 91 cases of SE in a single center in Barcelona. Of these, 31 patients received LCM. Patient characteristics were not significantly different between those who did and did not receive LCM. SE was diagnosed according to earlier studies 34, 50 and cessation of SE was defined as the disappearance of ictal symptoms and no pathologic EEG activity. The last drug administered prior to termination was defined as the effective drug, irrespective of the time between the administration of this drug and the cessation of SE. LCM was applied with a median loading dose of 400 mg and a maintenance dose of 200 mg/12 h. The total duration of SE before LCM use was on median 30 h (range 3-200 h). Overall, LCM was effective in 21 (67%) of 31 cases. When LCM was used earlier in the course of treatment (as second or third AED), the termination rate was significantly higher for those patients with LCM when compared to those without (84.6% vs. 47.8%). No significant difference in termination rate between these groups was seen when LCM was positioned later in the AED succession. Overall, efficacy was higher when LCM was administered earlier during the course of treatment: a clear order effect was visible, with 84.6% (11/ 13) of patients responding to LCM as the second or third drug compared to 55.6% (10/18) when LCM was given as the fourth or fifth drug. There was an overlap of two patients between this study 49 and those reported by Mir o et al., 51 with no specifics given. Sutter et al. 52 reported results from a retrospective comparative cohort study in patients with refractory SE employing historical cohorts from the University Hospital Basel. SE was diagnosed if seizures lasted >5 min or if a series of seizures emerged without recovery of mental function between the seizures. No significant differences in age, SE severity, or etiology were found between the cohorts. 52 LCM was deemed efficacious in 51% (23/45) of patients. Using univariate analyses, SE duration and seizure control were altered favorably, but nonsignificantly. After adjustment for age, mortality was significantly lower in patients treated with LCM. The authors concede that the reduction in mortality was confounded by the implementation of continuous EEG monitoring during the year prior to the cohort change. 52 Kellinghaus et al. 50 retrospectively compared the use of intravenous phenytoin (PHT) to intravenous LCM in 46 patients with refractory SE, defined as failure of the first and second anticonvulsants to stop SE. AEDs were considered successful when they were last introduced before seizure cessation. Pretreatment was the same in both groups using benzodiazepines and levetiracetam. SE ended in 40% of PHT patients and 33% of LCM patients. The patients in the PHT group had a higher rate of generalized convulsive seizures. Median latency from SE onset to LCM application was 19 h with a median dose of 400 mg, i.v., LCM (range 200-800 mg). SE was terminated after a median of 9.5 h. The authors conclude that LCM showed similar success rates to PHT in refractory SE with less risk of adverse events. 50 In a retrospective multicenter observational study by Garc es et al. (LACO-IV) , 53 data from 55 patients with SE treated in an emergency setting are reported. SE did not have to be refractory. SE cessation was defined as no clinical or EEG sign of seizure and AED response was defined as last AED introduced before SE cessation. Median LCM loading dose was 200 mg i.v. (range 50-400 mg). LCM ended 71% of SE episodes, with a mean time of 18 h, whereas cessation after <24 h from administration was achieved in 49% of SE episodes. A shorter latency from SE onset to LCM application significantly increased efficacy, whereas the comparison of efficacy between patients receiving LCM as first/second-line therapy or later (73.9% vs. 68.8%) revealed only a numerically better response for earlier positioning of LCM in AED succession. The authors note that patients in their study received LCM rather early compared to other reports and thus may not fully reflect the order effect seen in other studies. No significant differences were found for response to intravenous LCM in SE patients receiving prior sodium channel blockers or non-sodium channel-blocking AEDs.
Legros et al. 54 compared the efficacy of 200-400 mg loading doses of LCM in refractory SE and seizure clusters in a prospective observational study that included 25 patients; 21 patients had SE and 4 had seizure clusters (SC). Results were calculated summarily for all patients. SE was defined in accordance with Brophy et al. 55 and SE cessation was defined as no ictal EEG for at least the same day. A median of three other AEDs had failed before LCM application. The higher initial dose of 400 mg was significantly associated with a higher degree of early (<3 h) SE termination and nonsignificantly with a higher overall response rate. In total, 36% (9/25) of patients responded to LCM treatment. 54 Moreno Morales et al. evaluated the efficacy of LCM on convulsive SE (CSE) versus nonconvulsive SE (NCSE) in a prospective observational study. Of the 53 patients who were included, 23 had CSE and 30 had NCSE. 51 SE was diagnosed according to Kaplan et al. 47 LCM was deemed effective in terminating SE when no ictal EEG activity could be traced in both groups. All patients received LCM 400 mg i.v., over 30 min for 8 days following inclusion (mean dose of 390.6 mg). There were no significant LCM dosing differences between the two groups. CSE patients were significantly more likely to receive benzodiazepines. LCM was successful in terminating overall SE in 56.6% and similarly effective in CSE and NCSE (69.6 vs. 46.7%, respectively). In 90.6% of cases, LCM led at least to some (>30%) improvement. Specific mean time to termination or effect of LCM position in AED succession was not reported separately. 51 In a study that was not specifically designed to assess LCM efficacy but rather compare different AED strategies 57 prospectively studied LCM efficacy in seizure emergencies including seizure clusters and SE. In total, 23 of 38 patients in the study had SE, which was further divided into established (10/23), refractory (5/23), and super-refractory SE (8/23). LCM was effective in 8 of 10 patients who were nonresponsive to benzodiazepines (categorized as established SE) and in none of the super-refractory SE cases (eight patients). SE cessation was defined as the termination of clinical symptoms and of ictal activity on video-EEG without recurrence during the same hospital stay. The last drug before SE cessation was deemed effective. 57 Overall success in SE was 52% (12/23). "Immediate" resolution (<20 min after LCM application) was seen in 10 patients, whereas "early" (<4 h after LCM) was seen in two patients. No patients responded later than 4 h after LCM. One of the patients with absence SE had been described earlier as a case report 58 (see below). Lang et al. described an overall efficacy of 70% in patients with SE and SC upon intravenous LCM treatment. Overall, 19 patients with SC and 51 patients with SE were included, but efficacy and adverse events were not reported separately for these patients. 59 Furthermore, several case reports have been reported (Table 2) . Hawkes et al. 60 described two patients with refractory focal motor SE responsive to a single oral dose of 300 mg LCM as adjunctive AED. LCM was given as the third or fourth AED, respectively. Because SE cessation occurred 30 min after LCM application, the authors argue that LCM can be deemed the terminating agent in both cases. Spalletti et al. 61 described a 39-year-old man with refractory focal motor SE secondary to subdural hematoma who responded to LCM 200 mg i.v., given as a fourth AED. The authors note that the patient presented both with Jacksonian motor seizures associated with focal epileptiform discharges as well as cortical myoclonus associated with periodic lateralized epileptiform discharges (PLEDs). Focal motor seizures stopped <1 h after LCM application. Myoclonus persisted for another 3 days. PLED amplitude diminished 48 h after LCM application, in conjunction with myoclonus intensity. During the last 24 h before myoclonus cessation, negative myoclonus associated with low amplitude PLEDs (negative cortical myoclonus) was seen. Due to the parallel clinical improvement, the authors interpret this negative cortical myoclonus as a correlate of the antiepileptic effect of LCM. 61 Illan-Gara et al. describe a 51-year-old patient with breast cancer who developed NCSE as first manifestation of epilepsy following the administration of paclitaxel-cremophor for chemotherapy. LCM 200 mg i.v., led to clinical seizure termination after intravenous levetiracetam had already markedly improved EEG. 62 Fern andez-Torre et al. reported a patient with NCSE following multiple cerebral fat emboli during orthopaedic surgery. After extensive pretreatment with intravenous midazolam, intravenous levetiracetam and transient sedation with intravenous propofol and midazolam, the patient was given valproate and lacosamide. The exact succession of drugs is not mentioned, but it is suggested that LCM was given last. NCSE resolved after 2 weeks of AED treatment, but the patient was nonresponsive on day 21 after admission and later died.
63
A single case report by Sodemann et al. 64 describes efficacy of LCM 400 mg, i.v., in absence status epilepticus (ASE). Drug levels of preexisting levetiracetam (LEV), topiramate, and lamotrigine were not assessed in this case, and continuous EEG monitoring was not employed. That LCM is effective in ASE is strongly contested by other authors taking into account both their own data as well as general pathophysiologic considerations. Rather, a spontaneous ending of ASE in the case described by Sodemann et al. 65 is suggested. They describe a patient with idiopathic generalized epilepsy and acute ASE who failed to respond to 2 9 200 mg LCM applied intravenously under continuous EEG monitoring. 58 Hadjigeorgiou et al. describe three patients with refractory focal motor SE. Two patients had subdural hematoma, and one had brain metastasis. Seizures were acute and remote symptomatic (range 6 h-2 months). All patients were first treated with phenytoin and levetiracetam. LCM was the third drug in all cases. Oral administration of LCM 100 mg twice a day and subsequent dose increase to 200 mg twice a day fully controlled focal motor SE in all patients within 4 days (range 3-4 days). 66 A study designed to compare efficacy and tolerability of intravenous fosphenytoin to intravenous LCM in NCSE and recurrent NCS on intensive care units in a randomized design was started in 2012 (Treatment of Recurrent Electrographic Nonconvulsive Seizures [TRENdS] Study), but was terminated in 2015 ahead of the target of 200 randomized patients due to recruiting problems. In total, 74 patients were included, but the results are not yet published.
67,68

Use of LCM for Treatment of Children and Adolescents with SE
Because LCM is licensed for adolescents older than 16 years, administration of LCM in ages below that constitutes an off-label use, which might explain the limited number of reported cases. Only six case reports and series were published, all of which employed a retrospective design. 30, 33, 45, [69] [70] [71] Overall, data from 36 pediatric SE patients are available with success rates in terminating SE of 45-78%; for details, refer to Table 3 .
Poddar et al. retrospectively analyzed the efficacy and safety of LCM as add-on treatment in nine pediatric patients Table 3 . Efficacy and safety data from pediatric studies on the use of LCM in status epilepticus 70 Grosso et al. retrospectively analyzed data from eleven pediatric patients with a mean age of 9.4 years and SE. LCM was used at a mean initial bolus of 8.6 mg/kg, and was effective in ending seizures in five patients (45%). No serious adverse events were reported. 71 Arkilo et al. analyzed the efficacy and safety of LCM as an add-on treatment in 11 pediatric patients (mean age 5 years, range 4 weeks to 12 years, initial dose ranging between 4 mg/kg and 10 mg/kg) with SE (2/11), refractory SE (5/11) or super-refractory SE (4/11). It is the only study that describes treatment of LCM in SE in a newborn. 69 Overall LCM was successful in 72.8% (7/11) cases with regard to ending SE. In detail, LCM failed to terminate the SE in all cases of super-refractory SE. However, all cases of SE or refractory SE were successfully treated with LCM. No serious adverse events were reported. 69 A smaller case series from Jain et al. describes three patients with refractory tonic SE who were treated with intravenous LCM. In all cases, LCM was effective in ending the SE. For two of the three patients, adverse events were described, which manifested as delayed oculogyric crisis and chorea. 30 Overall, in 3 of 36 children (age range 4 weeks-17 years), side effects were described; however, no serious adverse events occurred in the studies in pediatric patients, [69] [70] [71] suggesting that LCM seems to be a safe and efficacious treatment option in SE in pediatric patients.
Overall Efficacy of LCM in SE
In total, 522 episodes of SE in 486 adults and 36 minors could be extracted from the literature, including the data already evaluated by H€ ofler and Trinka. 25 Efficacy data were available for a total of 471 episodes (51.7% female). Overall LCM efficacy was 57%, which is similar to the efficacy of 56% described by H€ ofler and Trinka in 2013. Disregarding the case reports, which can be presumed to suffer from publication bias with an overall efficacy of 88% (15 of 17 cases are responders), the efficacy from case series and studies alone is 56%. One has to note that these numbers have to be interpreted carefully, as they pool the efficacy in a wide range of SE types, include both nonrefractory and refractory cases, and are based on studies using different criteria and methods to diagnose both SE as well as drug efficacy. Detailed data concerning patient groups could not be extracted from all of the available literature. However, some further analysis was possible. Despite some differences in categorizing SE types, detailed semiology was available from 95% of the 471 episodes. Of those, 32% had focal motor SE, 17% had generalized convulsive SE (GCSE), and 50% had NCSE. Because GCSE might be associated with early brain damage and increased mortality, 72 anesthetics such as propofol and midazolam or thiopental will be introduced early on in the refractory course of SE. Although GCSE is treated early with sedating agents, the possible brain damage associated with focal motor SE (FMSE) is much less well established and thus patients are more likely to be treated with novel, nonsedating intravenous agents before starting anesthetics. Furthermore, NCSE is usually diagnosed with EEG, and a substantial proportion of patients with NCSE are likely to be treated in the intensive care unit where continuous or at least regular EEG monitoring is employed, a situation in which novel nonsedating agents might be favored. This is especially true as anesthetics have been associated with higher mortality in SE. 73 The efficacy of LCM with regard to different SE manifestations (NCSE, GCSE, and FMSE) was not accounted for in all of the included studies, probably due to small sample sizes. In those studies concerning adult patients that did, varying termination rates were reported among seizure types: those ranged from 91% 41 to 0%, 34 for GCSE with an overall efficacy of 61% (30/49). For NCSE, efficacy ranged from 100% 35 to 0%, 34 with an overall number of 57% (82/ 145); this was not significantly different than in GCSE (p = 0.68). Moreno Morales et al. 51 explicitly compared efficacy of LCM in CSE and NCSE and found a similar efficacy of 69.6% versus 46.7%, respectively. For FMSE, efficacy ranged from 100% 33, 73 to 50%, 38 with 92% (34/39) overall, which seems better than in GCSE (p = 0.013) and NCSE (p < 0.001).
LCM is currently not approved for use in SE. Consequently, most studies used LCM as an adjunctive therapy in patients with refractory SE. This impacts the evaluation of LCM efficacy and may have led to an underestimation of the efficacy of LCM in SE treatment. AEDs are commonly less effective in terminating SE when they are afforded a later position in the succession of anticonvulsive drugs, 74 which is reflected in the findings from several studies. The efficacy with later positioning decreased from 60% to 20%, 35 100% to 75%, 43 84.6% to 55.6%, 49 and 72.2% to 56.3%, 48 respectively. A longer time from seizure onset to LCM administration also significantly reduced treatment success. 53 The time from seizure onset to LCM application varied widely in the studies, ranging from a median of 22 h 59 to a median of 166 h 38 in studies where a median was calculated. Calculating efficacy with regard to time delay from SE onset to LCM application is confounded by the fact that a longer delay usually means a later position in the succession of AEDs, which in and of itself contributes to reduced efficacy.
Time from LCM application to termination of SE also varied widely, from several minutes 64 to as much as 10 days, 57 due to the fact that the last AED introduced before SE cessation was deemed the most effective in many of the studies. Dosing of LCM in the studies was mostly 200 or 400 mg, reflecting the approved doses of LCM. Doses as low as 25 mg are described in case reports. Only a few cases with doses >400 mg are described. 46, 51, [56] [57] [58] Legros et al. explicitly compared the efficacy of LCM 200-400 mg, i.v., and showed a significantly higher early response (<3 h) in the 400 mg group with no significant difference in overall response. 54 
Safety and Tolerability in SE
Data on the safety and tolerability from randomized-controlled trials (RCTs) showed a dose dependency with LCM 200 and 400 mg/day being fairly well tolerated with treatment-emergent adverse events (TEAEs) of usually mild or moderate intensity, whereas treatment discontinuation increased to 30% in patients treated with the 600 mg/ day. [13] [14] [15] [16] The most frequent TEAEs were dizziness, abnormal vision, diplopia, nystagmus, fatigue, tremor, ataxia, and other coordination abnormalities, as well as nausea and vomiting. Serious adverse events were rare and comprised seizures, dizziness, nausea, vomiting, nystagmus, and psychiatric disorders. Adverse events reported in postmarketing studies were similar to those reported in the RCTs. 26 Tolerability seemed lower when LCM was combined with other sodium-channel blockers, such as carbamazepine, oxcarbazepine, lamotrigine, and phenytoin. 75 Because LCM acts on voltage-gated sodium channels, treatment-induced atrioventricular (AV) block is a possible concern, especially in cases of a rapid intravenous LCM application. Using a loading dose of 12 mg/kg LCM over 30 min and an infusion rate of 0.4 mg/kg/min, a mean increase in PR interval of 7.3 msec was shown for a 400 mg/day, and of 11.9 msec for an 800 mg/day maintenance dose group. 76 In another study of 98 patients, two of them presented cardiac adverse events (1.8%). 53 A 77-yearold patient with ischemic cardiopathy showed an asymptomatic PR prolongation under a dosage of 200 mg/day LCM after previously administration of benzodiazepine LEV, and valproate (no concomitant dromotropic medication). Another 78-year-old patient with an NCSE and the comorbidity of an ischemic cardiopathy (dromotropic premedication with beta blocker and calcium antagonist) developed a third-degree AV block after the application of two doses of 200 mg LCM. Previously, LEV had been administrated. In both cases, LCM was initially effective and later reintroduced after implantation of a cardiac pacemaker. 53 The overall occurrence of adverse events in this study was 15.1%, which is comparably lower compared to other common AED used in SE and contained an AED-typical symptomatology such as somnolence 8.2%, nausea 4.1%, or dizziness 3.1%. 53 After rapid intravenous loading with LCM 200-400 mg, other cardiovascular symptoms such as hypotension and arrhythmia have occasionally been reported. 50 After the introduction of 400 mg LCM to a patient with chronic renal failure (creatine clearance of 40 ml/min/m 2 ), confusion and myoclonus were reported, which disappeared after a reduction of the daily LCM dosage to 300 mg/day. 54 Another patient from the same cohort showed an increase in frequency and severity after the introduction of LCM in the treatment of SE leading to a discontinuation of LCM application. These and other adverse events within the study (ataxia, vertigo) occurred at least 24 h after initiation of LCM treatment and were attributed to an accumulation of the maintenance dosage of LCM. 54 Moreover, a significant increase of alanine transaminase (ALT) in one patient with known chronic alcohol abuse and sepsis was reported during LCM treatment. ALT levels were already abnormal before LCM application and increased from 91 to 196 IU/L after the administration of LCM 200 mg. However, no clinical signs of hepatic dysfunction or failure became apparent. 54 Occasionally, adverse events like angioedema, allergic skin reactions, hypotension, or pruritus have been reported, without evidence for a substance-specific accumulation. 25, 77 In comparison with PHT, relevant cardiovascular side effects appear to be much rarer. 50 Overall, the symptomatology of adverse events under treatment with LCM seem to be comparable to that of common AEDs used in SE. 25, 54, 71, 77 Special Considerations in Populations with Renal, Hepatic, or Cardiac Impairment
Because LCM undergoes primarily renal elimination with an elimination half-life of 13 h, dose adaptation is warranted in patients with severe renal impairment or end-stage renal disease. 11, 12 A maximum dose of LCM of 300 mg should not be exceeded. Hemodialysis significantly decreases systemic LCM exposure by approximately 57%. 9 LCM dosage supplementation up to 50% of the divided daily dose should be considered directly after the end of hemodialysis. In addition, in patients with mild or moderate hepatic impairment, a maximum dose of 300 mg/day should not be exceeded. 9 Cardiac safety issues were analyzed in a pooled analysis 78 that showed a dose-dependent prolongation of PR interval from baseline to the end-of-maintenance from 1.4 msec (LCM 200 mg/day), 4.4 msec (LCM 400 mg/day), to 6.6 msec (LCM 600 mg/day). The frequency of first-degree AV block differed between 1.1% and 4.9% on LCM compared to placebo with 2.4-3.2%. Patients with AV block were allowed to continue the studies and apparently did not experience clinical side effects from the prolonged conduction time. No instance of second-or third-degree AV block was reported. Monitoring of electrocardiography (ECG) might be therefore considered in patients with known conduction problems and in those treated by PR interval-prolonging drugs such as carbamazepine, lamotrigine, and pregabalin. QTc intervals were not affected. Altogether, clinical practice shows a good cardiac tolerability of LCM.
Coadministration with other AEDs as well as other common medications seems straightforward, as LCM exhibits low potential for clinically relevant pharmacokinetic drugdrug interactions. 26 
Conclusion
In total, 522 episodes of SE could be extracted from the literature showing an overall LCM efficacy of 57%. Efficacy was comparable between use in nonconvulsive (57%) and generalized convulsive (61%) SE, while overall success rate was better in focal motor SE (92%). Head-to-head comparisons with established and other new anticonvulsants are desirable to clarify whether there are any real differences in efficacy. The strength of LCM is the lack of interaction potential and the option for intravenous use in emergency situations requiring rapid uptitration.
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